Target Price | $5.00 |
Price | $5.00 |
Deviation |
0.00%
register free of charge
|
Number of Estimates | 1 |
1 Analyst has issued a 2seventy bio price target 2026.
The average 2seventy bio target price is $5.00.
This is
0.00%
register free of charge
|
|
A rating was issued by 1 analysts: 0 Analysts recommend 2seventy bio to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the 2seventy bio stock has an average upside potential 2026 of
0.00%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 37.86 | 76.00 |
62.29% | 100.74% | |
Net Margin | -152.45% | -19.33% |
34.01% | 87.32% |
1 Analyst has issued a sales forecast 2seventy bio 2025 . The average 2seventy bio sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued a net profit forecast 2seventy bio 2025 . The average 2seventy bio net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.10 | -0.28 |
75.11% | 74.55% | |
P/E | negative | |
EV/Sales | 4.41 |
1 Analysts have issued a 2seventy bio forecast for earnings per share. The average 2seventy bio EPS is
This results in the following potential growth metrics and future valuations:
Analyst | Rating | Action | Date |
---|---|---|---|
Morgan Stanley |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
Leerink Partners |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
Analyst Rating | Date |
---|---|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Mar 14 2025 |
Locked
Leerink Partners:
Locked
➜
Locked
|
Mar 11 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.